

Attorney Docket No: 23546-07666US  
Client Ref: RTS-0297  
USSN: 09/920,671

### AMENDMENTS TO THE CLAIMS

1. (Previously presented): A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding CoREST (SEQ ID NO:11), wherein said compound specifically hybridizes with said nucleic acid molecule encoding CoREST (SEQ ID NO:11) and inhibits the expression of CoREST.
2. (Original): The compound of claim 1 which is an antisense oligonucleotide.
3. (Previously presented): The compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 14, 15, 17, 18, 19, 20, 21, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 80, 81, 82, 84, 86, 87, 88, 89, 90 or 91.
4. (Original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
5. (Original): The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.
6. (Original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
7. (Original): The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
8. (Original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
9. (Original): The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.
10. (Original): The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Attorney Docket No: 23546-07666US  
Client Ref: RTS-0297  
USSN: 09/920,671

11. (Previously presented): A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding CoREST (SEQ ID NO:11).

12. (Original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

13.(Original): The composition of claim 12 further comprising a colloidal dispersion system.

14. (Original): The composition of claim 12 wherein the compound is an antisense oligonucleotide.

15. - 25 (Canceled)